Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03797001 · ClinicalTrials.gov registry record · Phase 2
Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT03797001 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 102 participants.
The verdict
NCT03797001, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
REDHART2 is a randomized, double-blinded, placebo-controlled trial to determine the effects of Anakinra on peak aerobic exercise capacity measured with a cardiopulmonary test after 24 weeks in patients with recently decompensated systolic heart failure and increased systemic inflammation.
Interventions
- DRUG Placebo
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2024-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03797001
The ClinicalTrials.gov registry entry for NCT03797001 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03797001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03797001 about?
NCT03797001 is a clinical study titled "Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2". REDHART2 is a randomized, double-blinded, placebo-controlled trial to determine the effects of Anakinra on peak aerobic exercise capacity measured with a cardiopulmonary test after 24 weeks in patients with recently decompensated systolic heart failure and increased systemic inflammation.
What is the current status of trial NCT03797001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2019-01-04. Estimated completion is 2024-07-22.
What interventions are being tested in trial NCT03797001?
The interventions under investigation include: Placebo (DRUG), Anakinra (DRUG).
Who is sponsoring clinical trial NCT03797001?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.